A Phase 3 interventional study of lurasidone in Bipolar Depression, sponsored by Sumitomo Pharma America, Inc.. Completed at 151 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-04-14.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing lurasidone in Bipolar Disorder — 2 open to participants now, 2 under way, none of them phase 3. lurasidone · Bipolar Disorder.
Among the 17 studies testing lurasidone in Bipolar Disorder, this one is the 2nd largest by enrollment, is one of 3 that started in 2009, is one of 11 in phase 3, and was the 1st registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.
Browse Bipolar Disorder studies →2 of the 17 studies testing lurasidone in Bipolar Disorder are open now, in 2 countries. Recruiting first, the newest first:
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 16–65 · Healthy volunteers
Martin Lan · Sites in United States
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 817 is above the median of 64 across 1,279 interventional studies indexed under Bipolar Disorder.
Median enrollment 348 across the 17 interventional studies. Of the 14 that completed or were terminated, 12 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 17 have an industry lead sponsor. The 9 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
Sumitomo Pharma Co., Ltd. has 9 studies filed under Bipolar Disorder — fewer than ten, so there is no comparison to draw.
1 of the studies testing lurasidone in Bipolar Disorder that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05480150First Affiliated Hospital of Zhejiang UniversityChinese Longitudinal and Systematic Study of Bioplar Disorder | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing lurasidone in Bipolar Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: lurasidone
Lurasidone 20-120 mg/d Flexibly Dosed - 24 weeks
Number of Participants With Serious and Non-serious Treatment-emergent Adverse Events Who Have Completed 24 Weeks of Extension Study Treatment
Rate of treatment-emergent adverse events in subjects who have completed (ie, reached 6-week endpoint) of Study D1050235 (NCT00868452), Study D1050236 (NCT00868699) or Study D1050292 (NCT01284517)
Time frame: 24 weeks
Change From Open-label Extension Baseline to Week 24 (Month 6/LOCF Endpoint) in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
The MADRS is a clinician-rated assessment of the subject's level of depression. Ten items are rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of ten items: reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.
Time frame: 24 weeks
Change From Open-label Extension Baseline to Week 24 (Month 6/LOCF Endpoint) in Clinical Global Impressions Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)
This CGI-BP-S is a clinician-rated assessment of the subjects current severity of depression and ranges from 1="Normal, not ill" to 7="Very severly ill". Higher scores are associated with greater severity.
Time frame: 24 weeks
| Milestone | Lurasidone |
|---|---|
| Started | 817 |
| Completed | 559 |
| Not completed | 258 |
Rate of treatment-emergent adverse events in subjects who have completed (ie, reached 6-week endpoint) of Study D1050235 (NCT00868452), Study D1050236 (NCT00868699) or Study D1050292 (NCT01284517)
| participants | Lurasidone |
|---|---|
| Number of Participants With Serious and Non-serious Treatment-emergent Adverse Events Who Have Completed 24 Weeks of Extension Study Treatment | 529 |
The MADRS is a clinician-rated assessment of the subject's level of depression. Ten items are rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of ten items: reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.
| units on a scale | Lurasidone |
|---|---|
| Change From Open-label Extension Baseline to Week 24 (Month 6/LOCF Endpoint) in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | -4.4 ± 10.60 |
This CGI-BP-S is a clinician-rated assessment of the subjects current severity of depression and ranges from 1="Normal, not ill" to 7="Very severly ill". Higher scores are associated with greater severity.
| units on a scale | Lurasidone |
|---|---|
| Change From Open-label Extension Baseline to Week 24 (Month 6/LOCF Endpoint) in Clinical Global Impressions Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression) | -0.58 ± 1.325 |
Collected over 24 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurasidone | — | 24/813 (3%) | 246/813 (30.3%) |
| Event | Lurasidone |
|---|---|
| DepressionPsychiatric disorders | 6/813 |
| Depression SuicidalPsychiatric disorders | 2/813 |
| ManiaPsychiatric disorders | 2/813 |
| Suicide AttemptPsychiatric disorders | 2/813 |
| PancreatitisGastrointestinal disorders | 1/813 |
| Disease ProgressionGeneral disorders | 1/813 |
| HypersensitivityImmune system disorders | 1/813 |
| AppendicitisInfections and infestations | 1/813 |
| Hand FractureInjury, poisoning and procedural complications | 1/813 |
| Humerous FractureInjury, poisoning and procedural complications | 1/813 |
| Event | Lurasidone |
|---|---|
| AkathisiaNervous system disorders | 66/813 |
| HeadacheNervous system disorders | 63/813 |
| NauseaGastrointestinal disorders | 62/813 |
| InsomniaPsychiatric disorders | 52/813 |
| AnxietyPsychiatric disorders | 47/813 |
| ParkinsonismNervous system disorders | 43/813 |
Safety population - received at least one dose of study medication
| Age, Continuous(years) | Lurasidone |
|---|---|
| Mean | 42.7 ± 12.03 |
| Age, Categorical(Participants) | Lurasidone |
|---|---|
| <=18 years | 6 |
| Between 18 and 65 years | 790 |
| >=65 years | 17 |
| Sex: Female, Male(Participants) | Lurasidone |
|---|---|
| Female | 427 |
| Male | 386 |
| Region of Enrollment(participants) | Lurasidone |
|---|---|
| United States | 283 |
| Slovakia | 19 |
| Ukraine | 78 |
| Lithuania | 16 |
| Russian Federation | 31 |
| Colombia | 15 |
| India | 128 |
| France | 23 |
| Czech Republic | 108 |
| Canada | 14 |
| Poland | 12 |
| Romania | 9 |
| Peru | 12 |
| South Africa | 56 |
| Japan | 6 |
| Germany | 3 |
Showing the first 100 of 151 sites across 15 countries. Choose a country and city above to see the rest.
The record gives a start of Apr 2009, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →